Pms70 - Biosimilar and Originator Etanercept: Influence of Local Policy Measures and Practices on Market Dynamics Between Swedish Counties

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1784
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pms69 - Biosimilar and Originator Infliximab: Influence of Local Policy Measures and Practices on Market Dynamics Between Swedish Counties

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Observational Study of Inflammatory Arthritis Treatment by Etanercept Originator Switched to an Etanercept Biosimilar

Reumatologia
RheumatologyAllergyImmunology
2019English

GP2015: An Etanercept Biosimilar

BioDrugs
MedicineBiotechnologyPharmacology
2017English

SAT0161 Preliminary Real World Data on Switching Patterns Between Etanercept, Its Recently Marketed Biosimilar Counterpart and Its Competitor Adalimumab, Using Swedish Prescription Registry

2017English

Response To: ‘Mandatory, Cost-Driven Switching From Originator Etanercept to Its Biosimilar SB4: Possible Fallout on Non-Medical Switching’ by Cantini and Benucci

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2018English

FRI0103 One-Year Follow-Up of a Nationwide Cohort of Patients With Inflammatory Arthritis, Who Switched From Originator to Biosimilar Etanercept, Focusing on Patients Who Switched Back to Originator. An Observational Danbio Study

2018English

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review

Rheumatology and Therapy
2019English

Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study

BioDrugs
MedicineBiotechnologyPharmacology
2018English

Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition

JAMA network open
Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy